Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis

Netherlands Journal of Medicine

Volumn 54, Issue 2, 1999, Pages 46-62

  Michiels, J J ^a   Kutti, J ^a   Stark, P ^a   Bazzan, M ^a   Gugliotta, L ^a   Marchioli, R ^a   Griesshammer, M ^a   Van Genderen, P J J ^a   Briere J ^a   Kiladjian, J J ^a   Barbui, T ^a   Finazzi, G ^a   Berlin, N I ^a   Pearson, T C ^a   Green, A C ^a   Fruchtmann, S M ^a   Silver, R T ^a   Hansmann, E ^a   Wehmeier, A ^a   Lengfelder, E ^a   Landolfi, R ^a   Kvasnicka, H M ^a   Hasselbalch, H ^a   Cervantes, F ^a   Reilly, J T ^a   Demory, J L ^a   Gisslinger, H ^a   Guardiola, Ph ^a   Martyre M C ^a   Le Bousse Kerdiles M C ^a   Thiele, J ^a   more..

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Aspirin; Bone marrow histopathology; Essential thrombocythemia; Hydroxyurea; Idiopathic myelofibrosis; Interferon alpha; Myeloproliferative disorders; Polycythemia vera

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANAGRELIDE; BUSULFAN; COLLAGEN; HYDROXYUREA; INTERFERON; RETICULIN;

ARTICLE; BONE MARROW CELL; CELL STRUCTURE; CLINICAL FEATURE; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; ERYTHROCYTE COUNT; ERYTHROPOIESIS; GRANULOPOIESIS; HISTOPATHOLOGY; HUMAN; MEGAKARYOCYTE; MEGAKARYOPOIESIS; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; OSTEOSCLEROSIS; PHILADELPHIA 1 CHROMOSOME; PHLEBOTOMY; POLYCYTHEMIA VERA; THROMBOCYTE FUNCTION; THROMBOCYTHEMIA; TREATMENT PLANNING;

ASPIRIN; BONE MARROW; BONE MARROW TRANSPLANTATION; DIAGNOSIS, DIFFERENTIAL; FOLLOW-UP STUDIES; GRANULOCYTES; HUMANS; INTERFERONS; MEGAKARYOCYTES; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDERS; PLATELET AGGREGATION INHIBITORS; POLYCYTHEMIA VERA; PROGNOSIS; THROMBOCYTOPENIA;

EID: 0033047249     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-2977(98)00143-0     Document Type: Article

References (70)

1. Modan B. The epidemiology of polycythemia vera. Wasserman R. Polycythemia Vera and the Myeloproliferative Disorders. 1995;140-146 W.B. Saunders Company, Philadelphia, USA. Chapter 12.
2. Chaiter Y., Brenner B., Aghai E., Tatarsky I. High incidence of myeloproliferative disorders in Ashkezi Jews in northern Israel. Leuk Lymph. 7:1992;251-255.
3. Berglund S., Zettervall O. Incidence of polycythemia vera in a defined population. Eur J Haematol. 48:1992;20-26.
4. Dougan L.E., Mathews M.L.V., Armstrong B.K. The effect of diagnostic review on the estimated incidence of lymphatic and hematopoietic neoplasms in Western Australia. Cancer. 48:1981;866-872.
5. Carli P.M. Epidemiology of polycythemia vera in Côte d'Or Burgundy. Nouv Rev Fr Hematol. 36:1994;147-149.
6. Mesa RA, Tefferi A, Jacobsen SJ, Wollan PC, Silverstein MN, The incidence and epidemiology of essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County study. Blood 1997;90(suppl 1):abstract 1547.
7. Michiels J.J., Juvonen E. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group. Semin Thromb Hemost. 23:1997;339-347.
8. Stark P., Regiev A., Blickstein D., Lahav M., Shaklai M. Thrombotic complications in essential thrombocythemia with relatively low platelet counts. Am J Hematol. 56:1997;168-172.
9. Griesshammer M., Bangerter M., van Vliet H.H.D.M., Michiels J.J. Aspirin in essential thrombocythemia: status quo and quo vadis. Semin Thromb Hemost. 23:1997;371-377.
10. Ravandi-Kashani F., Schafer A.I. Microvascular disturbances, thrombosis and bleeding in thrombocythemia: current concepts and perspectives. Semin Thromb Hemost. 23:1997;479-488.
11. Cortelazzo S., Viero P., D'Emilio A., Rodeghiero F., Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol. 8:1990;556-562.
12. Van Genderen P.J.J., Michiels J.J. Erythromelalgia: a pathognomonic microvascular thrombotic complication in essential thrombocythemia and polycythemia vera. Semin Thromb Hemost. 23:1997;357-363.
13. Koudstaal P.J., Koudstaal A. Neurologic and visual symptoms in essential thrombocythemia: efficacy of low dose aspirin. Semin Thromb Hemost. 23:1997;365-370.
14. Tefferi A., Silverstein M.N., Petitt R.M., Meas R.A., Solberg L.A. Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of action, efficacy, toxicity, current indications. Semin Thromb Hemost. 23:1997;379-383.
15. Petrides P.E., Beykirch M.K., Trapp O.M. Anagrelide, a novel platelet lowering option in essential thrombocythaemia: treatment experience in 48 patients in Germany. Eur J Haematol. 61:1998;71-76.
16. Cortelazzo S., Finazzi G., Ruggeri M., et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. New Eng J Med. 332:1995;1132-1136.
17. Sterkers Y., Preudhomme C., Lai J-L., et al. Acute myeloid leukemia and myelodysplastic syndrome following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood. 91:1998;616-622.
18. Michiels J.J. Erythromelalgia and vascular complications in polycythemia vera. Semin Thromb Hemost. 23:1997;441-454.
19. Michiels J.J., Abels J., Steketee J., van Vliet H.H.D.M., Vuzevski V.D. Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann Int Med. 102:1995;466-471.
20. Michiels J.J., Koudstaal P.J., Mulder A.H., van Vliet H.H.D.M. Transient neurologic ischemic attacks and ocular manifestations in primary thrombocythemia. Neurology. 43:1993;1107-1110.
21. Scheffer M.G., Michiels J.J., Simoons M.L., Roelandt J.R.T.C. Thrombocythemia and coronary artery disease. Am Heart J. 22:1991;573-576.
22. Van Genderen P.J.J., Mulder P.G.H., Waleboer M., van de Moesdijk D., Michiels J.J. Prevention and treatment of thrombotic complications in essential thrombocythemia: efficacy and safety of low-dose aspirin. Br J Haematol. 97:1997;179-184.
23. Berlin N.I. The diagnosis and classification of the polycythemias. Semin Hematol. 12:1975;339-351.
24. Berk P.D., Goldberg J., Donovan P., Fruchtmann S.M., Berlin N.I., Wasserman L.R. Therapeutic recommendations in polycythemia vera. Semin Hematol. 23:1986;132-143.
25. Rozman C., Giralt M., Feliu E., Rubio D., Cortes M-T. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer. 67:1991;2658-2663.
26. 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. Blood. 89:1997;2319-2327.
27. Najean Y., Rain J.D. Treatment of polycythemia vera: The use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood. 90:1997;3370-3377.
28. Silver R.T. Interferon-alpha: Effects of long-term treatment for polycythemia vera. Semin Hematol. 34:1997;40-50.
29. Landolfi R., Marchioli R. European collaboration on low-dose aspirin in polycythemia vera (ECLAP): a randomized trial. Semin Thromb Hemost. 23:1997;473-478.
30. Pearson T.C., Messinezy M. The diagnostic criteria of polycythaemia rubra vera. Leuk Lymphoma. 22:(Suppl. 1):1996;87-93.
31. Michiels J.J. The Myeloproliferative Disorders: an historical appraisal and personal experiences. Leuk Lymphoma. 22:(Suppl 1):1996;1-14.
32. Pearson, Guthrie DL, Simpson J, Chinn S, Barosi G, Ferrant A, Lewis, SM, Najean Y. Red cell mass and plasma volume interpretation in normal adults. Br J Haematol. 1995;89:748-756.
33. Messinezy M., MacDonald L.M., Nunan T.O., Westwood N.B., Chinn S., Pearson T.C. Spleen sizing by ultrasound in polycythaemia and thrombocythaemia: comparison with SPECT. Br J Haematol. 98:1998;103-107.
34. Westwood N.B., Pearson T.C. Diagnostic applications of haematopoietic progenitor culture techniques in polycythaemias and thrombocythaemias. Leuk Lymphoma. 22:(Suppl 1):1996;95-103.
35. Pearson T.C., Wetherley-Mein G. The course and complications of idiopathic erythrocytosis. Clin Lab Haematol. 1:1979;189-196.
36. Najean Y., Triebel F., Dresch C. Pure erythrocytosis: reappraisal of a study of 51 cases. Am J Hematol. 10:1981;129-136.
37. Michiels J.J. Diagnostic criteria of the myeloproliferative disorders (MPD): essential thrombocythaemia, polycythaemia vera and chronic megakaryocytic granulocytic metaplasia. Neth J Med. 51:1997;57-64.
38. Ellis J.T., Peterson P. The bone marrow in polycythemia vera. Pathol Ann. 14:1979;383-403.
39. Ellis J.T., Peterson P., Geller S.A., Rappaport H. Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies. Semin Hematol. 23:1986;144-155.
40. Kurnick J.E., Ward H.P., Block M.H. Bone marrow sections in the differential diagnosis of polycythemias. Arch Pathol. 94:1972;489-499.
41. Kaplan M.E., Mack K., Goldberg J.D., et al. Long term management of polycythemia vera with hydroxyurea. A progress report. Semin Hem. 23:1986;167.
42. Fruchtman S.M., Mack K., Kaplan M.E., et al. From efficacy to safety: a PVSG report on hydroxyurea in patients with polycythemia vera. Semin Hematol. 34:1997;17.
43. Peterson P, Ellis JT, Geller Sa, et al., Increased incidence of acute leukemia in spent polycythemia vera following myelosuppressive therapy. Lab Invest 1986; 54:49(abstr).
44. Nand S., Messmore H., Fisher S.G., et al. Leukemia transformation in polycythemia vera: analysis of risk factors. Am. J. Hematol. 34:1990;32-36.
45. Weinfeld A., Swolin B., Westin J. Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications. Eur. J. Haematol. 52:1994;134-139.
46. Gruppo Italiano Studio Policitemia, Polycythemia vera: The natural history of 1213 patients. Ann Int. Med. 1995; 123:656-664.
47. Silver R.T. A new treatment for polycythemia vera: Recombinant interferon-alpha. Blood. 76:1990;664-665.
48. Taylor P.C., Dolan G., Ng J.P., et al. Efficacy of recombinant interferon-alpha in polycythemia vera: a study of 17 patients and an analysis of published data. Br. J. Haematol. 92:1996;55-59.
49. Sacchi S., Leoni P., Liberati M., et al. A comparison between treatment with phlebotomy alone and with inteferon alpha in patients with polycythemia vera. Ann. Hematol. 68:1994;247-250.
50. Cimino R., Rametta V., Matera C., et al. Recombinant interferon-alpha in the treatment of polycythemia vera. Am. J. Hematol. 44:1993;155-157.
51. Muller E.W., de Wolf T.H., Wijermans P.W. Long term treatment with interferon-alpha 2b for severe pruritus in patients with polycythemia vera. Br. J. Haematol. 89:1995;313-318.
52. Thiele J., Zankovich R., Schneider G., Kremer B., Fischer R., Diehl V. Primary (essential) thrombocythemia versus polycythemia vera rubra. A histomorphometric analysis of bone marrow features in trephine biopsies. Anal Quant Cytol Histol. 10:1988;375-382.
53. Thiele J., Wagner S., Degel C., et al. Megakaryocyte precursors in bone marrow tisue from patients with reactive thrombocytosis, polycythemia vera and primary (essential) thrombocythemia. Virch Archiv B Cell Pathol. 58:1990;295-302.
54. Thiele J., Zankovich R., Steinberg T., Kremer B., Fischer R., Diehl V. Primary (essential) thrombocythemia versus initial (hyperplastic) stages of agnogenic myeloid metaplasia with thrombocytosis - a critical evaluation of clinical and histomorphological data. Acta Haematol. 81:1989;192-202.
55. Thiele J., Kvasnicka H.M., Werden C., Zankovich R., Diehl V., Fischer R. Idiopathic primary osteo-myelofibrosis: a clinico-pathological study on 208 patients with special emphasis on evolution of disease features, differentiation from essential thrombocythemia and variables of prognostic impact. Leuk Lymphoma. 22:1996;303-317.
56. Georgii A., Vykoupil K.F., Buhr T., et al. Chronic myeloproliferative disorders in bone marrow biopsies. Path Res Pract. 186:1990;3-27.
57. Georgii A., Buhr T., Buesche G., Kreft A., Choritz H. Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies. Leuk Lymphoma. 22:(Suppl 1):1996;15-29.
58. Thiele J, Kvasnicka HM, Diehl V, Fischer R, Michiels JJ. Clinicopathological diagnosis and differential criteria of thrombocythemias in various myeloproliferative disorders by histopathology, histochemistry and immunostaining from bone marrow biopsies. Leuk Lymphoma 1998; in press.
59. Varki A.J.I.T., Lottenberg R., Griffith R., Reinhard E. The syndrome of idiopathic myelofibrosis. Medicine. 62:1983;353-371.
60. Njoku O.S., Lewis S.M., Catovsky D., Gordon-Smith E.C. Anaemia in myelofibrosis: its value in prognosis. Br J Haematol. 54:1983;79-89.
61. Visani G., Finelli C., Castelli U., et al. Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol. 75:1990;4-9.
62. Hasselbalch H., Jenssen B.A. Prognostic factors in idiopathic myelofibrosis: a simple scoring system with prognostic significance. Eur J Haematol. 44:1990;172-178.
63. Dupriez B., Morel P., Demory J-L. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 88:1996;1013-1018.
64. Kvasnicka H.M., Thiele J., Werden C., Zankovich R., Diehl V., Fischer R. Prognostic factors in idiopathic (primary) osteomyelofibrosis. Cancer. 80:1997;708-719.
65. Cervantes F., Pereira A., Esteve J., et al. Identification of "short-lived" and "long-lived" patients at presentation of idiopathic myelofibrosis. Br J Haematol. 97:1997;635-640.
66. Cervantes F., Pereira A., Esteve J., Cobo F., Rozman C., Monserrat E. The changing profile of idiopathic myelofibrosis: a comparison of the presenting features of patients diagnosed in two different decades. Eur J Haematol. 60:1998;101-105.
67. Reilly J.T., Snowden J.A., Spearing R.L., et al. Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases. Br J Haematol. 98:1997;96-102.
68. Martyré M.C., Romquin N., Le Bousse-Kerdilès M.C., et al. Transforming growth factor-b and megakaryocytes in the pathogenesis of idiopathic myelofibrosis. Br J Haematol. 88:1994;9-16.
69. Martyré M.C., Le Bousse-Kerdilés M.C., Romquin N., et al. Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis. Br. J. Haematol. 97:1997;441-448.
70. + hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia. Blood. 88:1996;4534-4546.